MLH1 and gastric cancer: Modification in DNA methylation (e.g. Reprimo, hMLH1) frequently detected in gastric cancer tissues as well as in serum or plasma specimens in patients with gastric cancer, while seldom or absent in controls, suggests its potential application as a non-invasive biomarker [11, 12].